UroGen Pharma (NASDAQ:URGN) Stock Price Up 4.5% - Should You Buy?

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report)'s share price shot up 4.5% during mid-day trading on Wednesday . The company traded as high as $10.91 and last traded at $11.11. 12,087 shares changed hands during mid-day trading, a decline of 98% from the average session volume of 500,716 shares. The stock had previously closed at $10.63.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on URGN shares. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price target on shares of UroGen Pharma in a report on Monday, March 10th. HC Wainwright reduced their price target on shares of UroGen Pharma from $64.00 to $55.00 and set a "buy" rating on the stock in a research report on Tuesday, March 11th. Finally, LADENBURG THALM/SH SH assumed coverage on shares of UroGen Pharma in a research note on Wednesday, February 19th. They set a "buy" rating and a $31.00 price objective on the stock. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $38.20.

UroGen Pharma Stock Performance

The company has a market capitalization of $460.53 million, a price-to-earnings ratio of -3.19 and a beta of 0.80. The firm has a 50-day simple moving average of $10.72 and a two-hundred day simple moving average of $11.40. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last posted its quarterly earnings data on Monday, March 10th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.69) by ($0.11). The company had revenue of $24.57 million during the quarter, compared to analyst estimates of $25.25 million. As a group, sell-side analysts forecast that UroGen Pharma Ltd. will post -3.12 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other UroGen Pharma news, insider Mark Schoenberg sold 4,551 shares of the business's stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $11.14, for a total value of $50,698.14. Following the completion of the transaction, the insider now directly owns 145,666 shares of the company's stock, valued at approximately $1,622,719.24. The trade was a 3.03 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Jason Drew Smith sold 7,379 shares of the business's stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $11.14, for a total transaction of $82,202.06. Following the completion of the transaction, the general counsel now owns 26,468 shares of the company's stock, valued at $294,853.52. This trade represents a 21.80 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 5.10% of the company's stock.

Institutional Trading of UroGen Pharma

Large investors have recently made changes to their positions in the company. Intech Investment Management LLC bought a new stake in shares of UroGen Pharma during the third quarter worth $155,000. Charles Schwab Investment Management Inc. boosted its position in shares of UroGen Pharma by 9.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 90,493 shares of the company's stock worth $1,149,000 after buying an additional 7,576 shares during the period. FMR LLC grew its holdings in shares of UroGen Pharma by 575.1% during the third quarter. FMR LLC now owns 23,090 shares of the company's stock worth $293,000 after buying an additional 19,670 shares in the last quarter. BNP Paribas Financial Markets raised its position in UroGen Pharma by 221.8% in the 3rd quarter. BNP Paribas Financial Markets now owns 8,546 shares of the company's stock valued at $109,000 after buying an additional 5,890 shares during the last quarter. Finally, Verition Fund Management LLC bought a new stake in UroGen Pharma in the 3rd quarter valued at approximately $168,000. Institutional investors own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.